Does BHC pay a dividend?

The cached stock data on this page does not show a positive dividend yield for BHC. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does BHC stock do?

Diversified pharmaceutical and medical device manufacturer focusing on ophthalmology (Bausch + Lomb), gastroenterology (Salix), and dermatology. Business relies on high-margin branded products to service a massive legacy debt load.

What is BHC stock's price target?

This cached page does not contain a precise model fair value for BHC.

The TradeMates model verdict for BHC is HOLD with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.

Is BHC a good dividend stock?

BHC is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

BHC (BHC) Stock Analysis

Q: Is BHC stock a good investment?

The cached TradeMates AI model rates BHC as HOLD with an investment score of 48/100. The AI model sees a company with strong operational cash flow ($1.4B) but a crippled balance sheet. The HOLD reflects a balance between the recent +55% momentum and the $21B debt burden. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Operational excellence and massive FCF yield are trapped behind a $21B debt wall and existential patent litigation on Xifaxan.

Investment score: 48/100

The AI model sees a company with strong operational cash flow ($1.4B) but a crippled balance sheet. The HOLD reflects a balance between the recent +55% momentum and the $21B debt burden.

View the full interactive analysis